Citius Pharmaceuticals (NASDAQ:CTXR) Releases Quarterly Earnings Results, Misses Estimates By $1.34 EPS

Citius Pharmaceuticals (NASDAQ:CTXR) posted its quarterly earnings results on Friday. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of $0.39 by ($1.34), FiscalAI reports. The firm had revenue of $1.67 million during the quarter, compared to the consensus estimate of $18.79 million.

Citius Pharmaceuticals Price Performance

Shares of NASDAQ CTXR traded down $0.02 during mid-day trading on Friday, hitting $0.70. 516,793 shares of the stock traded hands, compared to its average volume of 1,069,212. The company has a market cap of $15.67 million, a PE ratio of -0.29 and a beta of 1.05. Citius Pharmaceuticals has a twelve month low of $0.57 and a twelve month high of $2.48. The firm has a 50 day simple moving average of $0.79 and a two-hundred day simple moving average of $0.92.

Institutional Trading of Citius Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Heights Capital Management Inc. bought a new position in Citius Pharmaceuticals in the 4th quarter valued at approximately $622,000. XTX Topco Ltd grew its holdings in Citius Pharmaceuticals by 572.8% during the 4th quarter. XTX Topco Ltd now owns 107,118 shares of the company’s stock worth $83,000 after acquiring an additional 91,196 shares during the last quarter. Asset Advisory Group Inc. acquired a new position in Citius Pharmaceuticals in the 4th quarter valued at approximately $46,000. Finally, NewEdge Advisors LLC bought a new position in shares of Citius Pharmaceuticals during the second quarter valued at $40,000. 16.88% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

CTXR has been the topic of a number of recent analyst reports. D. Boral Capital reiterated a “buy” rating and issued a $6.00 target price on shares of Citius Pharmaceuticals in a research report on Wednesday, March 11th. Weiss Ratings restated a “sell (e+)” rating on shares of Citius Pharmaceuticals in a research note on Friday, March 27th. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $6.00.

About Citius Pharmaceuticals

Citius Pharmaceuticals is a clinical‐stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital‐acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.

One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter‐related bloodstream infections without catheter removal.